Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
Bayer announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer...
As a strategic step to better support growing demand and strengthen future service capacity, Quintara Biosciences announced that its Boston area laboratory...
The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, announced that two research awards focused on improving outcomes for...
First partnership announced under Verge Labs' platform-first model; Tenacia will apply Verge's AI platform and proprietary multimodal...
Leading regenerative medicine innovators unite to deliver seamless stem cell banking and personalized biologic solutions for physicians and patients nati...
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the ...
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the nextâ€...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, announced th...
As pharmaceutical manufacturers face increasing pressure to maintain production continuity, ensure regulatory compliance, and manage ageing equipment, the ...
Strategic partnership integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's CDMO services, giving developers a single-source path fr...
Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform&nbs...
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agon...
© 2026 Biopharma Boardroom. All Rights Reserved.
